Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
NCT04878952 is an interventional trial sponsored by NRG Oncology. As of 21 Nov 2026, it was terminated. It studies Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and 1 more condition. The registry lists an enrollment of 3 participants at 5 sites in 1 country. The registry lists a start date of 26 Aug 2021 and a primary completion date of 12 Aug 2024. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04878952 |
| Status | Terminated |
| Study type | Interventional trial |
| Lead sponsor | NRG Oncology |
| Enrollment | 3 |
| Registered sites | 5 |
| Countries | 1 |
| Conditions | Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and Recurrent Non Small Cell Lung Cancer |
| Start | 26 Aug 2021 |
| Primary completion | 12 Aug 2024 |
| Study completion | 12 Aug 2024 |
| Last update posted | 8 May 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Wellspan Health - Chambersburg
Chambersburg
- Wellspan Health - Ephrata
Ephrata
- Wellspan Health - Gettysburg
Gettysburg
- Wellspan Health - Lebanon
Lebanon
- Wellspan Health - York
York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT04878952
Each answer restates registry values shown on this page.
What is NCT04878952?
NCT04878952 is an interventional trial sponsored by NRG Oncology. It studies Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III and 1 more condition.
Who leads NCT04878952?
The registry names Nitin Ohri, MD (principal investigator, NRG Oncology) as the overall official.
Where does NCT04878952 run?
The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.
When did NCT04878952 end?
The registry lists a primary completion date of 12 Aug 2024 and a study completion date of 12 Aug 2024. The sponsor last updated the record on 8 May 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.